17 September 2019

To: Users of EP37, 1st ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of a correction made to CLSI document EP37, Supplemental Tables for Interference Testing in Clinical Chemistry, 1st ed., regarding the dabigatran concentrations listed on page 26 in Table 1, Testing Concentrations for Exogenous Interferents. The correction is described below. These revisions will assist users of the document in obtaining accurate information when conducting experiments on interference testing.

Table 1. Testing Concentrations for Exogenous Interferents:

The original concentrations for dabigatran were listed as:

- Highest drug concentration under therapeutic treatment: 1.75E+01 mg/dL
- Highest drug concentration under therapeutic treatment: 3.71E+02 µmol/L
- Recommended test concentration: 5.25E+01 mg/dL
- Recommended test concentration: 1.11E+03 µmol/L

The revised concentrations for dabigatran are:

- Highest drug concentration under therapeutic treatment: 3.00E−01 mg/dL
- Highest drug concentration under therapeutic treatment: 6.37E+00 µmol/L
- Recommended test concentration: 9.00E−01 mg/dL
- Recommended test concentration: 1.91E+01 µmol/L

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service at customerservice@clsi.org or +1.610.688.0100.

We appreciate your commitment to CLSI and regret any inconvenience.